Centogene finds diagnostic and predictive biomarker for Gaucher disease

04 Sep 2023
www.pharmaceutical-technology.com
Centogene finds diagnostic and predictive biomarker for Gaucher disease
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Centogene finds diagnostic and predictive biomarker for Gaucher disease
Preview
Source: Pharmaceutical Technology
Multiple biomarkers have been identified for the disease, however, these were not exclusive to Gaucher disease. Image Credit: vektorbird / Shutterstock.
Centogene has published data about the use of lyso-Gb1 (glucosylsphingosine) as a sensitive diagnostic and predictive biomarker for Gaucher disease.
The study was published in the open-access MDPI journal, Diagnostics, and showed that lyso-Gb1 could be used to predict the clinical course of patients with Gaucher disease.
Recommended Reports
Centogene finds diagnostic and predictive biomarker for Gaucher disease
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Imiglucerase Biosimilar in Gaucher Disease GlobalData
Centogene finds diagnostic and predictive biomarker for Gaucher disease
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - ACT-10041239 in Demyelinating Diseases GlobalData
View allCompanies IntelligenceCentogene GmbHView all
Gaucher disease is a rare inherited metabolic disorder caused by mutations in the beta-glucocerebrosidase (GBA1) gene, responsible for producing a fat-breaking enzyme, glucocerebrosidase.
Decreased activity of the enzyme causes fat accumulation in the cells causing symptoms such as liver enlargement, anaemia, bone pain, and spleen enlargement.
Multiple biomarkers have been identified for the disease. However, these were present in other diseases and not exclusively in Gaucher disease. Lyso-Gb1 is a more specific biomarker for Gaucher’s, and it can be used to both diagnose the disease and monitor its progression.
The confirmation of the biomarker serves as an important step forward in rare disease diagnostics. GlobalData has identified Gaucher disease as one of the four rare diseases with a limited number of clinical trials and products.
GlobalData is the parent company of Pharmaceutical Technology.
The study (NCT02416661) evaluated 160 treatment native individuals from multiple countries. The blood was collected using CentoCard, Centogene’s dried blood spot (DBS) collection kit, and was analysed for GBA1 gene mutations and making a GD diagnosis.
Centogene’s clinical neurogenetics director Tobias Böttcher said: “This important international study has helped to set the standard for Gaucher disease care – from diagnosis and prognosis to treatment and monitoring.
“The progressive increase in lyso-Gb1 levels in untreated Gaucher patients suggests that these patients could benefit from treatment, such as enzyme replacement therapy.”
Diagnostics have been a successful area for Centogene, generating €31.4m ($33.9m) in sales in 2022, as per the company’s financial report. The profits were driven in part by CentoGenome, a whole genome sequencing tool that can detect various rare diseases, including Gaucher’s, Parkinson’s, and spinal muscular atrophy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.